Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MOH To Inaugurate National Basic Medicine System In 2009

This article was originally published in PharmAsia News

Executive Summary

At the Seventh World Congress on Health Economics, the Department of Planning and Finance under China's Ministry of Health disclosed that the national basic medicine system will be implemented nationwide this year. MOH will formulate and issue the national basic medicine catalog (2009 edition), which includes more than 300 Western medicines and 300 TCMs. The agency proposes cancelling the adjustment fee for basic medicines, starting with all pilot health care institutions and basic level hospitals such as rural and community hospitals. This will be defined more clearly in the health care reform plan. Public hospital reform will depend on government subsidies: if public financing provides full subsidies, drug dispensing fees will not be imposed nor medical service charges raised. (Click here for more - Chinese Language)

You may also be interested in...



COVID-19: Gilead To Fill Remdesivir Supply Gap In EU

As the US firm prepares to ramp up production of the antiviral for use in coronavirus patients, a debate is growing over whether changes could be made to EU rules that prevent the importation of generic drugs produced under a compulsory license.

Pipeline Watch: Phase III Readouts For Daridorexant And Efbemalenograstim

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Executives On The Move: New CEOs At Ipsen, Herantis Pharma And Oncopetides

BeiGene gets a new chief business executive and there are new CMOs at Cellectar Biopharma, MacroGenics and Reata Pharmaceuticals.

UsernamePublicRestriction

Register

ID1125347

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel